Script section containing code for Liveperson Chat Solution

Hoover's - A D&B Company - We Make It Easier
I'm Ready to Subscribe
Special Offers
DNBi. Leverage D&B's credit assessment tools.

Icagen, Inc. · Durham, NC United States

4222 Emperor Blvd.,
Ste. 350
Phone: 919-941-5206
DurhamNCFax: 919-941-0813
27703
United StatesMap Map This Company
  • Company Profiles
  • Competitive Landscapes
  • Industry Reports

Buy Reports

For a Hoover's Free Trial, Call
(866) 444-8642
or
Chat Now

Icagen, Inc. Rankings

Company Description

Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with Johnson & Johnson subsidiary McNeil Consumer & Specialty Pharmaceuticals. Shortly thereafter Icagen announced a deal collaborating with Pfizer on the development of epilepsy and pain treatments. Then, in 2011, the company decided to just go ahead and be acquired by Pfizer.

To read the full description: Subscribe Now
left-headIcagen, Inc. Reports
right-head

No subscription, no problem.

Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.

Shop Reports
Shop Reports

Financials

Company TypePrivateSingle Location
Fiscal Year-EndDecember
2010 Employees38
More Icagen, Inc. Financials

Executives

20 executives listed for Icagen, Inc.'s Durham, NC location.

ChairmanCharles SandersE-mail
President, CEO, and DirectorP. Kay WagonerE-mail
EVP Finance and Corporate Development, CFO, and TreasurerRichard KatzE-mail

More Icagen, Inc. Executives

Sponsored Links